FDA Launches C3TI Program To Accelerate Pragmatic Trial Workflows

Regulatory affairs teams designing trials under active INDs now have a structured pathway to embed Bayesian statistical methods, selective safety data collection, and pragmatic clinical practice designs directly into CDER review engagement. The FDA's C3TI Demonstration Program formalises enhanced sponsor-agency communication at critical protocol milestones, with implications for how study design decisions are documented and defended through the IND lifecycle.

The program targets three pre-specified project areas: Bayesian Statistical Analysis (BSA), Selective Safety Data Collection (SSDC), and Streamlined Trials Embedded in Clinical Practice (STEP). Each area is scoped to trials intended to support new drug approvals or labeling changes under an active pre-IND or IND. Eligibility criteria are project-specific, and sponsors should consult the corresponding project-area webpages before submitting a proposal.

Accepted sponsors can expect a formal initial meeting with the responsible IND review team and relevant CDER subject matter experts, followed by a tailored engagement cadence tied to protocol development and study start-up. CDER has indicated that inspection activity associated with accepted trials may follow a quality-by-design approach, meaning oversight is calibrated to the innovative elements of the specific design rather than applied uniformly.

For regulatory affairs leads, the operational read is direct: earlier FDA feedback on key design decisions reduces the risk of late-stage protocol amendments and the associated validation and documentation burden. For QA directors, the reference to fit-for-purpose inspection processes signals that quality systems documentation may need to reflect the non-standard design elements explicitly, particularly where Bayesian monitoring or SSDC principles alter standard data collection workflows under 21 CFR Part 312.

Participation is currently scoped to CDER-regulated products; eligibility for CBER- or CDRH-regulated products has not been confirmed in the published FAQ.

The program's scalability objective, generating transferable case studies and best practices across the three project areas, positions C3TI Demonstration Program outcomes as potential reference material for future ICH-aligned guidance on adaptive and pragmatic trial design.

Source: FDA CDER via What's New: Drugs RSS Feed, 1 October 2026.